MYC genes have both essential roles during normal development and exert oncogenic functions during tumorigenesis. Expression of a dominant-negative allele of MYC, termed OmoMYC, can induce rapid tumor regression in mouse models with little toxicity for normal tissues. How OmoMYC discriminates between physiological and oncogenic functions of MYC is unclear. We have solved the crystal structure of OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in the same manner as the MYC/MAX heterodimer. OmoMYC attenuates both MYC-dependent activation and repression by competing with MYC/MAX for binding to chromatin, effectively lowering MYC/MAX occupancy at its cognate binding sites. OmoMYC causes the largest decreases in promoter occupancy and changes in expression on genes that are invaded by oncogenic MYC levels. A signature of OmoMYC-regulated genes defines subgroups with high MYC levels in multiple tumor entities and identifies novel targets for the eradication of MYC-driven tumors.
INTRODUCTION
A large body of evidence shows that the deregulated and enhanced expression of one of three members of the MYC gene family (MYC, MYCN, MYCL) contributes to the genesis of multiple human tumors. 1 MYC proteins are transcription factors that bind to virtually all promoters with an open chromatin structure as well as to thousands of enhancers together with an obligate heterodimerization partner, MAX (for recent reviews, see Dang et al.
1
; Kress et al.
2
; Wolf et al.
3 ). They can both activate and repress genes transcribed by RNA polymerase II and, in some circumstances, enhance expression of all genes. In addition, MYC proteins can stimulate transcription of genes transcribed by RNA polymerases I and III.
Depletion of MYC in tissue culture or deletion of MYC or MAX genes during mouse development shows that MYC/MAX complexes have essential functions during embryonic development and are necessary for growth of multiple cell types in vivo and in culture. [4] [5] [6] This correlates with the observation that multiple target genes of MYC encode proteins involved in basic cellular processes, including protein translation, cell cycle progression, DNA synthesis and intermediary metabolism. 1 A plethora of mutations that initiate tumorigenesis leads to constitutive, growth factorindependent expression of MYC. During tumor progression, there is a strong selection for further increases in MYC expression to supra-physiological levels, suggesting that such high levels of MYC provide an additional advantage to tumor cells. 7, 8 Two models have been proposed to account for this selective pressure: in one, oncogenic levels of MYC acquire new functions not shown by physiological MYC such as effects on the tumor microenvironment, 9 angiogenesis and response to hypoxia, 10, 11 resistance to antimitogenic signals, 12, 13 as well as stem cell function and metastasis. 14 In the second model, oncogenic MYC levels drive physiological processes such as translation to supraphysiological levels and tumor-specific phenotypes arise as stress responses to these primary events. 15, 16 The clearest demonstration that physiological and oncogenic functions of MYC can be discriminated comes from the study of a dominant-negative allele of MYC, termed OmoMYC. 17 Mice expressing OmoMYC in a doxycycline-inducible manner display rapid regression of lung adenocarcinomas, glioblastomas and pancreatic tumors but show only mild and fully reversible effects on proliferation in normal tissues. 9, 17, 18 As consequence, intermittent induction of OmoMYC ('metronomic treatment') enables long-term suppression of tumor growth arguing that therapeutic strategies that mimic OmoMYC may have significant efficacy for the treatment of human tumors. was replaced by a serine were treated with 100 μM H 2 O 2 where indicated. SDS-PAGE was performed under reducing or non-reducing conditions (± DTT) and blots probed with an α-HA antibody. CDK2 was used as a loading control (n = 4). *, nonspecific bands; upper arrow, covalently linked dimer; lower arrow, monomer; vec, empty vector control; Omo, HA-OmoMYC; CS, HA-OmoMYC(CS) mutant. (d) Immunoprecipitation of FLAG-tagged OmoMYC with α-FLAG antibody in U2OS cells expressing exogenous HA-tagged OmoMYC or MYC (HAtagged or doxycycline-induced untagged). Co-immunoprecipitated proteins were compared with 8% (α-FLAG and α-MYC immunoblots) or 4% (α-HA and α-MAX immunoblots) input material (n = 3). *, heavy chain; DOX, doxycycline; vec, empty vector control. Mutations that distinguish OmoMYC from MYC are highlighted in red. Boxes on the right highlight the carboxy-terminal disulfide bridge (top), the hydrogen bond network involving N77 (middle) and hydrogen bonds bridged by two water molecules between T63 (bottom). Images were generated using PyMOL. (b represents basic region; HLH: helix-loop-helix region; Zip: leucine zipper). (b) Crystal structure of the OmoMYC homodimer bound to a consensus E-box. The CACGTG motif is highlighted in blue. The boxes on the right illustrate basespecific interactions of one arm of the OmoMYC homodimer (green) to one half of the palindromic E-box sequences of the doublestranded DNA (gray). For comparison, base-specific protein-DNA contacts of MYC in the MYC/MAX structure (1NKP) 21 are illustrated in the upper box. (c) Interactions that distinguish the OmoMYC homodimer (upper panel) from the MYC/MAX heterodimer (lower panel) as deduced from the crystal structures. Mutations of OmoMYC relative to MYC are shown as red dots. Dotted lines indicate interactions of the carboxy-terminus (boxed), which is not present in the MYC/MAX crystal structure and can therefore not be compared reliably. IA, interaction.
RESULTS
OmoMYC is a highly stable homodimer and forms a tight protein/DNA complex To understand how OmoMYC regulates gene expression, we expressed a histidine-tagged OmoMYC protein in E. coli and purified the recombinant protein to homogeneity using sequential metal affinity and cation exchange chromatography (Supplementary Figures S1a and b) . In parallel, we purified recombinant proteins encompassing the basic region/helix-loophelix/leucine zipper (b/HLH/Zip) region of MYC and full-length MAX (Supplementary Figure S1b) . We pursued crystallization of OmoMYC in the absence and presence of an oligonucleotide carrying an E-box binding site and solved both the apo-and the DNA-bound structure of OmoMYC (Figures 1a and b +  +  ----+  +  ----------+  +  +  +  +  +   +  +  +  +  +  +  --------+  +  +  +  --+  +  +  +   +  -+  -+  -+  -+  -+ Table S2a and b). Superposition of the apo-and DNA-bound OmoMYC complex showed that the two structures are nearly identical with rms deviations of 0.60 Å for all main chain atoms with the exception of the basic region, which was not resolved in the apo structure (Supplementary Table S2a Table S3) . Consistent with the intended design of OmoMYC, three out of the four mutations introduced to generate the OmoMYC protein led to additional interactions between the two monomers (Figures 1a  and c) . The newly introduced hydrogen bonds are formed between two threonine residues (T63) bridged by water molecules as well as the asparagines (N77) of both molecules with an additional interaction to lysine 81 in monomer B. Hydrophobic interactions are observed between two isoleucine residues (I70) and to leucine 66. Further hydrophobic interactions are observed between threonine 63 and leucine 66. Glutamine 76, which is also a mutated residue in OmoMYC, faces away from the interface.
Differences in protein/protein interactions between the OmoMYC homodimer and the MYC/MAX heterodimer are not limited to the mutated residues, but can also be identified throughout the entire interface ( Figure 1c) . OmoMYC also displayed a disulfide bridge formed by its penultimate cysteine residues (Figure 1a; Supplementary Figure S1d) . Using the 'Protein interfaces, surfaces and assemblies' (PISA) tool, 22 we estimated that the protein/protein interface of the OmoMYC homodimer is more stable than the MYC/MAX heterodimer (ΔG = − 41 kcal/mol versus − 33 kcal/mol; Supplementary Figures S1e-g ), suggesting that OmoMYC preferentially forms homodimers.
In the DNA-bound complex, OmoMYC binds to the major groove of the DNA by forming a scissor-like structure at the E-box, which is stabilized via phosphate-backbone interactions and base-specific interactions. The latter are mediated via a histidine (H12), glutamate (E16), arginine (R20) triad in the basic region (Figure 1b; Supplementary Figures S2a and b) . A comparison of the protein/DNA interface of OmoMYC to one of the MYC/MAX DNA complex indicates that the basic region of both complexes assume the same contacts to DNA, suggesting that OmoMYC could compete with MYC/MAX for E-box binding 21 (Supplementary Figure S2c; Supplementary Tables S2a and b). We therefore studied the DNA-binding properties of all three proteins using a fluorescently labeled oligonucleotide carrying a consensus E-box sequence. Recombinant MAX proteins bound to this sequence with high affinity, whereas binding of MYC was only detectable at micromolar protein concentrations (Figures 2a  and b; Supplementary Figure S3a) . Consistent with previous results, MAX and MYC co-operated in DNA binding and MYC/MAX complexes bound DNA with a higher affinity than MAX homodimers (Figures 2a and b; Supplementary Figures S3a and b) . OmoMYC homodimers bound DNA with an affinity that is even higher than that of MYC/MAX complexes, both in the absence and presence of reducing agent (Figures 2a and b ; Supplementary Figure S3a) . Furthermore, OmoMYC formed heterodimers with MYC that bound to DNA with an intermediate affinity (Figures 2a  and b ; Supplementary Figures S3a and b) . We were unable to unequivocally ascertain whether OmoMYC/MAX heterodimers bind DNA.
To demonstrate that OmoMYC homodimers exist in cells, we first briefly exposed cells stably expressing OmoMYC to conditions known to oxidize cysteine residues (100 μM H 2 O 2, 5 min). 23 On treatment of cells with H 2 O 2 , virtually all OmoMYC molecules migrated with a molecular weight expected of a covalently linked homodimer in a non-reducing SDS-PAGE (Figure 2c ). Mutation of the penultimate cysteine to serine (OmoMYC-CS) confirmed that this residue was involved in dimerization under oxidizing conditions ( Figure 2c ). Second, we stably co-expressed both HAtagged and FLAG-tagged alleles of OmoMYC in U2OS cells and precipitated lysates with α-FLAG antibodies ( Figure 2d ). These experiments confirmed that OmoMYC forms homodimers in cells.
The cells express a doxycycline-inducible allele of MYC 24 and we also expressed a HA-tagged allele of MYC in cells expressing FLAGOmoMYC. Probing the immunoprecipitates with α-MYC, α-HA and α-MAX antibodies showed that OmoMYC also forms heterodimers with both MYC and MAX in cells (Figure 2d ), consistent with previous results. 25 Notably, doxycycline-mediated induction of wtMYC or expression of HA-MYC significantly reduced binding of OmoMYC to MAX, but had little effect on homodimerization of OmoMYC, arguing that OmoMYC homodimers are more stable than OmoMYC/MYC and OmoMYC/MAX heterodimers ( Figure 2d ). We concluded that OmoMYC forms stable homodimers and heterodimers with MYC and MAX in cells and that both OmoMYC homodimers and OmoMYC/MYC heterodimers bind specifically to DNA.
OmoMYC blunts promoter invasion by oncogenic MYC levels To determine how OmoMYC binds to chromatin, we stably expressed HA-tagged OmoMYC in U2OS cells that express a doxycycline-inducible allele of MYC, which we have previously characterized 24 ( Figure 3a ). We performed chromatinimmunoprecipitation coupled with high-throughput sequencing (ChIP-sequencing) using an α-HA and an α-MYC antibody, which recognizes the amino-terminal 262 amino acids of MYC that are not present in OmoMYC. ChIP results of individual genes and inspection of multiple individual regions of the genome showed that overall binding patterns of MYC and OmoMYC were very similar ( Figure 3b , Supplementary Figures S4a and b) . This result was confirmed by a global analysis of all MYC binding sites, which showed a highly significant overlap in binding sites ( Figure 3c ). Consistent with these findings, de novo motif analysis confirmed that OmoMYC binding sites were enriched in both consensus (CACGTG) and non-consensus E-box (CANNTG) binding sites (Supplementary Figure S4c) . In addition, OmoMYC, like MYC, showed a preference for promoters and enhancers with an open chromatin structure even in the absence of a cognate binding site 26, 27 (Supplementary Figures S4d and e) . U2OS cells express relatively low levels of endogenous MYC that are identical to levels found in several non-transformed proliferating cell lines; upon doxycycline induction, levels increase to those found in colon carcinoma and HeLa cells. 28 These 'oncogenic' levels of MYC bind to additional sites not occupied by physiological MYC levels ('promoter invasion'). 24, 29 Quantitative analyses show that promoters differ strongly in the MYC concentration at which binding is half-maximal (EC 50 ) and that EC 50 values stratify functionally different classes of MYC target genes. 28 To test how OmoMYC affects chromatin association of MYC, we performed ChIP-sequencing for MYC at both concentrations in the presence and absence of OmoMYC. Expression of OmoMYC reduced binding of MYC at both promoters and nonpromoter binding sites (Figure 3d ). Consistent with its molecular properties, the decrease in MYC binding caused by OmoMYC was stronger on consensus E-box sequences than on non-consensus E-boxes or on binding sites that lacked an E-box ( Figure 3d , Supplementary Figure S5a) .
Importantly, the decrease in MYC binding was not uniform for all promoters. Rather, OmoMYC had little influence on MYC binding at promoters that are highly occupied by physiological levels of MYC and to which no additional MYC is recruited when 24 The x axis shows recruitment in the absence, y axis in the presence of OmoMYC. The P-value was calculated using a linear model and a t-test with an offset of 1. MYC recruitment was calculated by counting the number of tags in a region of ± 100 bp around the summit of the MYC peak, input was subtracted and a fold change between +DOX and − DOX was calculated.
MYC levels increase to supra-physiological levels (Figure 3e ). In contrast, OmoMYC decreased the recruitment of MYC ('invasion') to promoters upon doxycycline induction (Figure 3e) . Indeed, the effect of OmoMYC on MYC binding correlated with the EC 50 values for the respective gene (Supplementary Figure S5b) . One way to rationalize these findings is the suggestion that OmoMYC competes with MYC/MAX complexes for binding to DNA. MYC/ MAX binding at promoters that are highly occupied by (Figure 4a ). To obtain a global picture of OmoMYC-dependent gene regulation, we performed RNA-sequencing in the presence and absence of OmoMYC without and 30 h after induction of ectopic MYC expression. The analysis showed that OmoMYC significantly attenuated both transcriptional activation and repression by MYC (Figure 4b) . We have previously shown that the change in expression of a given gene in response to doxycycline-mediated induction of MYC correlates with the change in occupancy of its promoter. 24, 28 Consistent with the DNA-binding data, attenuation of gene regulation by OmoMYC was not uniform but was strongest on genes that respond to an increase from physiological to supraphysiological level of MYC (Figure 4c, red) . The simplest model to account for this observation is that OmoMYC competes with MYC/MAX complexes on DNA to lower MYC/MAX affinity to its cognate binding sites and thereby blunts the 'invasion' of lowaffinity promoters. In support of this notion, we found that the OmoMYC-dependent change in expression correlated with the decrease in MYC binding over all MYC target genes (Figure 4d ).
To test whether specific DNA-binding is required for OmoMYC's effects on gene regulation, we stably expressed two alleles of OmoMYC: one OmoMYC(HER), in which the DNA-binding triad in the basic region H12-E16-R20 is mutated to alanine and a second, which carried alanine substitutions only at H12 and E16 (OmoMYC (HE)), as mutation of the two homologous residues in MYC (H359A-E363A) is sufficient to abolish specific E-box recognition (B Amati, personal communication). We confirmed that both OmoMYC(HER) and OmoMYC(HE) accumulate in the nucleus upon stable expression in cells (Supplementary Figures S6a and b) . ChIP experiments confirmed that both OmoMYC(HER) and OmoMYC (HE) are compromised in their ability to recognize target promoters on DNA (Figure 4e ). The analysis of individual genes showed that both OmoMYC(HE) and OmoMYC(HER) are severely compromised in their ability to inhibit MYC-dependent transcription (Figure 4f ). This was confirmed by RNA-sequencing, which showed that mutation of the basic region largely, but not completely abolished the repressive effect of OmoMYC on MYCdependent transcription (Figure 4c, Supplementary Figure S6c) .
Collectively, the data argue that the predominant mode, by which OmoMYC inhibits MYC-dependent gene regulation, is the formation of DNA-binding homodimers that compete with MYC/MAX heterodimers for their target DNA.
OmoMYC-regulated genes define a signature characteristic of multiple MYC-driven tumors Gene set enrichment (GSE) analyses showed that OmoMYC reverted expression of multiple well-characterized MYC target gene signatures (Figure 5a ). This suggested that OmoMYC might blunt an expression program that is characteristic of human tumors characterized by high MYC expression. GSE analyses showed that this is indeed the case and that OmoMYC target genes identify tumors with high MYC levels in human neuroblastoma, multiple myeloma, medulloblastoma, colon carcinoma and Burkitt lymphoma (Figures 5b and c) . Notably, the most consistent overlap was observed for genes that are repressed by OmoMYC, which largely correspond to genes that are activated by MYC. Although OmoMYC-activated (MYC-repressed) genes discriminated medulloblastomas and multiple myelomas with high MYC levels, they did not reliably identify colon carcinoma and human Burkitt lymphoma, possibly indicating that direct repression by MYC is not a predominant mode of gene regulation in these entities. Consistent with this notion and the human data, OmoMYC-repressed genes, but not OmoMYC-activated genes, discriminated both pre-tumoral stages from control lymphocytes and also frank lymphomas from pre-tumoral stages in mouse models of MYC-driven lymphomagenesis 7 ( Figure 5d ). In contrast, sets of high affinity MYC target genes that are not competed or regulated by OmoMYC discriminated normal B-cells from both pre-lymphomagenic cells and lymphomas, but were unable to discriminate pre-lymphomagenic cells from frank lymphomas (Supplementary Figure S7a) . Furthermore, OmoMYC had little effect on expression of genes regulated by endogenous MYC during mitogenic stimulation of fibroblasts (Figure 5e ). OmoMYCregulated genes also discriminated pancreatic carcinomas with high MYC expression and particularly bad prognosis from less aggressive carcinomas (Supplementary Figure S7b) . We concluded that OmoMYC regulates a group of MYC target genes that is characteristic of tumor entities expressing high levels of MYC across multiple entities.
Identification of OmoMYC target genes critical for growth of MYCdependent tumor cells GSE analysis of the OmoMYC-regulated genes revealed a spectrum of functions that have been identified in previous analyses of MYC target genes 1 (Supplementary Figure S8a) . We tumors, as previous work had established that MYC levels and function are critical for growth of these tumors in vivo. 24 We generated cell lines that express OmoMYC in a doxycyclineinducible manner in KRAS/p53 mut cells (KPC; Figure 6a ). OmoMYC suppressed both adherent and anchorage-independent growth of KPCs (Figure 6b, Supplementary Figures S8b and c) . RNAsequencing showed that genes regulated by OmoMYC in KPCs are highly similar to those regulated in U2OS cells (Supplementary Figure S8d) .
We next generated a focused shRNA library that targets genes that are activated by MYC and repressed by OmoMYC (Figure 6c,  Supplementary Table S5) . Each of the genes was covered by five shRNAs, and the representation of individual shRNAs was determined by high-throughput sequencing after 4 days of induction. This focused screen identified three significant hits, BOP1, RPN13 (also known as ADRM1) and ATAD3A (Figure 6d , Supplementary Table S6 ). Both MYC and OmoMYC bound to the promoters of BOP1 and ATAD3A confirming they are direct targets of both (Supplementary Figures S9a and b) . Like the entire set of OmoMYC-regulated genes, expression of all three genes correlated with MYC expression in several human tumor entities (Supplementary Figure S9c) . Independent work had established that expression of each of these genes is enhanced in multiple human tumors and can be prognostic for tumor outcome. [30] [31] [32] [33] Indeed, inhibitors of ribosome biogenesis (for example, of RNA Polymerase I) and inhibitors of ADRM1 are currently being explored for tumor therapy. 32, 34 We confirmed that both inhibitors of RNA Polymerase I (CX-5461) and of ADRM1 (RA 190) suppress growth of KPCs, validating the results of the screen (Figure 6e ). Titration of both inhibitors revealed no evidence for synergy, consistent with the fact that they inhibit independent cell biological processes (Supplementary Figure S9d) .
The most significant hit in this screen is ATAD3A, a protein that promotes fusion of mitochondria. 35 ATAD3A is a downstream target of the mTOR pathway and required for cell growth in Drosophila and Caenorhabditis elegans. 35, 36 Consistent with these observations and the screening results, shRNA-mediated depletion of ATAD3A attenuated growth of KPCs (Figures 6f and g ). We confirmed that ATAD3A localizes to mitochondria (Figure 7a ). Changes in mitochondrial dynamics alter mitochondrial metabolism in response to cell growth and metabolism. We speculated that uncoupling of both processes might lead to the accumulation of reactive oxygen species. In support of this notion, shRNAmediated suppression of ATAD3A using two shRNAs caused an increase in mitochondrial reactive oxygen species that correlated with the decrease in ATAD3A expression (Figures 7b and d) . Depletion of PLD6, a MYC-induced gene that encodes a phospholipase that initiates mitochondrial fusion also sharply increased the reactive oxygen species levels in mitochondria, supporting the notion that this increase is due to altered mitochondrial dynamics 37 ( Figure 7c ). Maintaining a redox balance is of particular importance for transformed cells owing to a prevalence of anabolic processes that consume reducing equivalents. Indeed, depletion of ATDA3A caused MYC-dependent apoptosis in U2OS cells (Figure 7e) . We concluded that ATAD3A-dependent changes in mitochondrial dynamics are critical for the survival of cells that express high levels of MYC.
DISCUSSION
Here, we have solved the structure and studied the properties of OmoMYC to understand how OmoMYC can discriminate between physiological and oncogenic functions of MYC. Consistent with the intended design, we find that OmoMYC forms homodimers that are stabilized by interactions of residues that are mutated in OmoMYC. 20 The overall structure of OmoMYC (including the DNAbinding domain) is highly similar to the structures of other HLH/ Zip proteins. OmoMYC homodimers interact with DNA in the same manner as MAX homodimers and MYC/MAX heterodimers. 21, 38 This suggests a model, in which OmoMYC competes with MYC/ MAX complexes for binding to DNA, and is in line with previous observations that ectopically expressed OmoMYC can be chromatin-immunoprecipitated at MYC target sites. 25 In support of this model, we found that mutant alleles of OmoMYC with reduced affinity to E-box containing DNA are compromised in their ability to antagonize MYC-dependent gene expression. We confirm previous findings that OmoMYC forms heterodimers with MYC and MAX, 25 although both estimation of heterodimer stability from the crystal structure and immunoprecipitation experiments from cells suggest that OmoMYC/MYC and Omo-MYC/MAX heterodimers have lower stabilities than OmoMYC homodimers. OmoMYC/MYC heterodimers are capable of binding to DNA. Therefore the reduction in chromatin association of MYC caused by OmoMYC homodimers is attenuated by formation of OmoMYC/MYC heterodimers. Furthermore, it is possible, that OmoMYC/MYC heterodimers regulate transcription similar to MYC/MAX heterodimers. If this is the case, the biological effects of OmoMYC are attenuated by OmoMYC/MYC heterodimers, implying that the design of more potent OmoMYC alleles is possible that shift the dimerization balance towards even more stable homodimer formation.
OmoMYC competes with MYC/MAX heterodimers on chromatin and thereby reduces their occupancy at cognate binding sites. OmoMYC blunts the binding of MYC to low-affinity sites ('promoter invasion') that is characteristic of the high levels of MYC observed in many human tumors, but has a significantly weaker effect on MYC binding to sites bound by physiological MYC levels (Figure 8 ). We hypothesize that the ability of OmoMYC to discriminate different classes of target genes is owing to the fact that MYC binding to promoters with an apparent high affinity is stabilized by local protein/protein interactions in addition to contacts with DNA ( Figure 8) . 28 This suggestion is supported by the recent identification of core promoter factors that bind to MYC and stabilize its binding to promoters and by biochemical and mathematical modeling analyses arguing that both binding of MYC to DNA and to promoter-bound factors is required to account for the chromatin-binding behavior of MYC in cells. 27, 28, 39, 40 Many expression profiles have been identified that are characteristic for tumor entities or subgroups that express particularly high MYC or N-MYC levels. OmoMYC reverts a MYC-dependent gene expression program that is recognizable in multiple human and mouse tumor entities, providing a model of how it can have broad antitumor activity. At the same time, OmoMYC has significantly less effect on gene expression programs of normal proliferating cells, correlating with its low toxicity in vivo.
Genes that responded particularly strongly to OmoMYC did not encode proteins that are functionally linked to one specific cellular process. We therefore performed an shRNA screen to identify downstream targets via which OmoMYC may suppress tumor cell growth. The screen identified BOP1, which is part of a trimeric complex ('PeBoW') that is essential for processing and maturation of mammalian 5. The P-values were calculated using a paired two-tailed Student's t-test.
known as RPN13), an ubiquitin acceptor on the proteasome; 42 and ATAD3A, a calcium-regulated protein involved in mitochondrial dynamics and transport from the ER to the mitochondrion. 35, 43 Ribosome biogenesis and protein translation are essential for normal cell growth. Nevertheless, both processes are enhanced to supra-physiological levels in MYC-driven tumors and targeting these processes opens specific therapeutic windows. 16, 44 Likewise, targeting ADRM1 using small molecule inhibitors opens a wide therapeutic window between normal and tumor cells. 32 Similarly, we find that cells expressing high levels of MYC have an enhanced dependence on ATAD3A for survival, suggesting that targeting ATAD3A may also be effective against MYC-dependent tumor cells. ATAD3A has anti-apoptotic functions in tumors, potentially via its effects on mitochondrial dynamics. 33, 45 Collectively, our findings suggest that individual genes encoding rate-limiting proteins involved in basic cell biological processes respond to the difference between physiological and supra-physiological MYC levels and that OmoMYC specifically inhibits tumor cell growth as it suppresses expression of this group of genes. A similar picture has emerged from studies of nucleotide biosynthesis genes: despite pervasive binding of MYC to promoters of nucleotide biosynthetic enzymes, 46 deregulation of a single rate-limiting enzyme, phosphoribosyl-pyrophosphate synthetase 2 (PRPS2), promotes the increased nucleotide biosynthesis of MYCtransformed cells. 47 A complete understanding of how to mimic OmoMYC's efficacy with small molecule inhibitors will therefore require an analysis of its target genes in an in vivo setting.
MATERIALS AND METHODS
A detailed description of all materials and methods can be found in the Supplementary Information.
Expression and purification of recombinant OmoMYC, MYC and MAX protein OmoMYC, MYC (aa353-434) and MAX were expressed as N-terminally Histagged or GST-tagged proteins in E.coli and chromatographically purified using the ÄKTA protein purification systems (GE Healthcare, Chicago, IL, USA).
Crystallization of OmoMYC
OmoMYC apo crystals were grown using the vapor diffusion method in sitting drops and analyzed at beamline ID23-1 at the ESRF (Grenoble, France) to a resolution of 1.95 Å. The DNA-bound OmoMYC complex was generated by crystallizing his-tagged OmoMYC in the presence of an E-box oligonucleotide. 38 The data set was collected at beamline 14.1 (BESSY II, Berlin, Germany) to a resolution of 2.7 Å. The structures were solved via Phaser by molecular replacement using the MYC/MAX dimer (1NKP) 21 as initial search model. PDB codes for OmoMYC are: 5I4Z (apo structure) and 5I50 (DNA-bound structure).
Gel mobility shift assays
Increasing concentrations of recombinant OmoMYC, MAX and MYC were used for binding reactions with a double-stranded, 5'CY3-labeled DNA substrate (CM1). 48 Where indicated, the antibodies were added before DNA addition. The K d values were calculated using Prism (GraphPad Software, La Jolla, CA, USA) assuming complete dimer formation with a four-parameter nonlinear regression.
Cell culture U2OS tet-on-MYC cells 24 and KPCs (Ptf1a+/Cre;Kras+/LSL-G12D;p53loxP/ R172H) were cultured according to standard conditions; U2OS were authenticated via STR Analysis; KPCs were a kind gift of Jens Siveke (Technical University of Munich, Germany). All cell lines were routinely tested for mycoplasma contamination.
Pooled negative-selection shRNA screening A custom shRNA library directed against OmoMYC target genes (Supplementary Table S5 ) was cloned into the inducible lentiviral vector RT3GEPIR. 49 KPC cells were transduced with the pooled library and cultivated in the presence or absence of doxycycline for 4 days. shRNA sequences were PCR recovered from genomic DNA of harvested cells and changes in shRNA frequencies were determined by next-generation sequencing with an Illumina GAIIx (Illumina, San Diego, CA, USA).
Bioinformatic analysis and statistics
Information on data processing for ChIP-and RNA-sequencing is at GEO: GSE77328. For binned data, the mean of each bin is plotted. Sorting of the binned data was done using independent experiments. Regression lines were estimated using linear models and corresponding P-values were calculated using two-tailed t-distribution. Statistical significant differences between two regression lines were determined using an analysis of covariances. The P-values for box plots were calculated with nonparametric two-tailed Wilcoxon-Mann-Whitney tests. 
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